Figure 2.

ELISA results for in vitro sarcoidosis‐like granulomas. Granulomas were developed using PBMCs from subjects with confirmed sarcoidosis. Four different groups were studied: control, PBMC from sarcoidosis patients (not challenged with microparticles); granuloma, PBMCs challenged with microparticles; MIA602, granuloma treated with MIA602; and methylprednisolone, granuloma treated with methylprednisolone. Data shown are mean cytokine concentrations ± SEM at 48 h after challenge with MAB microparticles. For each group, five replications were included. Data are from one experiment that is representative of three separate experiments.